Equities analysts predict that Vistagen Therapeutics Inc (NASDAQ:VTGN) will report earnings per share of ($0.28) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.32) per share during the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The business is expected to report its next quarterly earnings report on Thursday, July 5th.
On average, analysts expect that Vistagen Therapeutics will report full-year earnings of ($1.08) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.09) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Vistagen Therapeutics.
Several research firms have recently issued reports on VTGN. Oppenheimer began coverage on shares of Vistagen Therapeutics in a report on Thursday, May 24th. They set a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Friday, March 30th. Finally, UBS Group began coverage on shares of Vistagen Therapeutics in a research note on Thursday, May 24th. They issued an “outperform” rating and a $6.00 target price on the stock.
Shares of Vistagen Therapeutics traded down $0.04, hitting $1.45, on Monday, MarketBeat reports. 200 shares of the company were exchanged, compared to its average volume of 960,750. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65. The company has a market cap of $32.52 million, a price-to-earnings ratio of -0.95 and a beta of 0.29.
A number of hedge funds and other institutional investors have recently bought and sold shares of VTGN. Ladenburg Thalmann Financial Services Inc. increased its stake in Vistagen Therapeutics by 131.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 104,414 shares of the company’s stock valued at $116,000 after acquiring an additional 59,338 shares during the period. Sphera Funds Management LTD. increased its stake in Vistagen Therapeutics by 17.8% in the fourth quarter. Sphera Funds Management LTD. now owns 1,247,251 shares of the company’s stock valued at $1,384,000 after acquiring an additional 188,865 shares during the period. Finally, Sabby Management LLC bought a new stake in Vistagen Therapeutics in the fourth quarter valued at about $2,352,000. 9.43% of the stock is currently owned by institutional investors and hedge funds.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.